Full Potential of 6-Mercaptopurine in IBD May Remain Untapped

Am J Gastroenterol. 2020 Dec;115(12):2109-2110. doi: 10.14309/ajg.0000000000000769.

Authors

Burton I Korelitz¹, David B Sachar², Judy Schneider³

Affiliations

¹ Hofstra-Northwell School of Medicine, Chief Emeritus of Gastroenterology, Lenox Hill Hospital, New York, New York, USA.
² Chief Emeritus of Gastroenterology and Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Lenox Hill Hospital, Northwell Health System, New York, New York, USA.

PMID: 32740082
DOI: 10.14309/ajg.0000000000000769

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunosuppressive Agents / therapeutic use*
Inflammatory Bowel Diseases / drug therapy*
Mercaptopurine / therapeutic use*
Treatment Outcome

Substances

Immunosuppressive Agents
Mercaptopurine